Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding Moon Ki ChoiByung-Jin AhnWon Ki Kang Original Article 06 March 2010 Pages: 5 - 11
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity Deyan Y. YosifovPlamen T. TodorovMartin R. Berger Original Article 23 February 2010 Pages: 13 - 25
Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies Philipp KieweMartin NeumannAgnieszka Korfel Original Article 24 February 2010 Pages: 27 - 33
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets Dae Ho LeeSang-We KimJung-Shin Lee Original Article 25 February 2010 Pages: 35 - 39
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial Matteo Dalla ChiesaGianluca TomaselloRodolfo Passalacqua Original Article 05 March 2010 Pages: 41 - 48
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity Chen Guang YangJoseph CiccoliniCédric Mercier Original Article 05 March 2010 Pages: 49 - 56
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma Donna E. ReeceDan SullivanA. Keith Stewart Original Article 20 March 2010 Pages: 57 - 67
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer N. XenidisK. NeanidisS. Kakolyris Original Article 11 March 2010 Pages: 69 - 73
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma Fernando RiveraMaica GalánOn Behalf of the Spanish Cooperative Group for Digestive Tumour Therapy (TTD) Original Article 03 March 2010 Pages: 75 - 82
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin Luke A. WittenburgLiam BissonDouglas H. Thamm Original Article 20 March 2010 Pages: 83 - 92
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity Carla M. M. PradoIsac S. F. LimaMichael B. Sawyer Original Article 05 March 2010 Pages: 93 - 101
The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer M. F. UllahH. Y. KhanS. M. Hadi Original Article 06 March 2010 Pages: 103 - 110
Serological immune responses to influenza vaccine in patients with colorectal cancer Ajithkumar PuthillathDonald L. TrumpMarwan G. Fakih Original Article 05 March 2010 Pages: 111 - 115
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids Eva GottfriedSebastian RogenhoferMarina Kreutz Original Article 09 March 2010 Pages: 117 - 126
Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement In Hae ParkSun Young KimSook Ryun Park Original Article 11 March 2010 Pages: 127 - 136
Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor Natalie M. G. M. AppelsMaria J. BolijnJan H. M. Schellens Original Article 13 March 2010 Pages: 137 - 145
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin Han Ying BaoWei Jia FangNong Xu Original Article 11 March 2010 Pages: 147 - 152
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial Peter GibbsPhilip R. ClinganTracey J. Brown Original Article 24 March 2010 Pages: 153 - 163
Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs Kenneth M. RassnickJosephia R. MuindiDonald L. Trump Original Article 21 March 2010 Pages: 165 - 171
Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts Xiangpeng ZhengBeth A. GoinsGary D. Fullerton Original Article 21 March 2010 Pages: 173 - 182
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase Nicholas O. RomanBetty K. SamulitisRobert T. Dorr Original Article 26 March 2010 Pages: 183 - 192
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model Terence O’ReillyHeidi A. LanePaul M. J. McSheehy Original Article 30 May 2010 Pages: 193 - 200
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen Akinobu KuritaShoichi KadoTeruo Yokokura Original Article 31 March 2010 Pages: 201 - 213
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer J. FeliuP. BorregaM. González-Barón Clinical Trial Report 07 October 2010 Pages: 215 - 221
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial Binghe XuZefei JiangJunlan Yang Clinical Trial Report 12 October 2010 Pages: 223 - 230
Effects of methimazole on the elimination of irinotecan Jessica M. van der BolTheo J. VisserRon H. J. Mathijssen Short Communication Open access 01 August 2010 Pages: 231 - 236
The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1 Ken-ichi FujitaMinako SugiyamaYasutsuna Sasaki Short Communication 02 September 2010 Pages: 237 - 241
Cytokeratin 8/18 monoclonal antibody was dissimilar to anti-cytokeratin CAM 5.2 Shao-Chuan WangFong-Lin ChenChih-Ping Han Letter to the Editor 14 December 2010 Pages: 243 - 244
In response to Dr. Han’s comments Mattheos BobosAristotelis Bamias Letter to the Editor 20 November 2010 Pages: 245 - 245